SUBMISSION INFORMATION

ISPOR is strongly committed to diversity. The Society’s Strategic Plan and core values embrace excellence through encouragement and acceptance of diverse ideas, cultures, and disciplines. Issue Panel submissions are encouraged from all stakeholders and are evaluated based on merit. ISPOR also aims to reflect the diversity of its membership in all endeavors and encourages consideration of diversity in abstract submissions. Diversity dimensions include (but not limited to) gender, career stage, ethnicity, race, education, sexual orientation, region/geographic location, physical disability, and religion. Additional information can be found at the Society’s  Diversity Policy.

  • ISPOR issue panels are designed to stimulate real debate on new or controversial topics in health economics and outcomes research or use of outcomes research in healthcare decision making.
  • A successful issue panel will debate an important and/or timely HEOR issue. Each panelist is expected to provide a different perspective on the issue.
  • To assure lively discussion, panelists should be from different institutions and/or work environments.
  • Example of an Issue Panel session proposal submission is available here (downloadable PDF).

SUBMISSION INSTRUCTIONS

Issue panel submissions should be organized as follows:

STEP 1: GENERAL INFORMATION

  • Acknowledgements: Submitting authors/submitters must agree to read and agree to ISPOR submission guidelines, ISPOR being an in-person only event, and AI-Assisted Content Disclosure.
  • Title: Provide a title that accurately describes the issue and is framed as a question. The title should be in title case, 225 character limit (including spaces). Examples:
    • Multi-Indication Pricing: Do We Want It? Can We Operationalize It?
    • Designing a Patient-Centered Value Framework to Guide Shared Decision Making Oncology: Why, What, and How?
    • Are Existing Health Technology Assessment Requirements Inadequate for Establishing Value for Potentially Transformative Gene Therapies?
  • Submitter Email
  • Subject of Debate:  successful issue panel will debate an issue and have multiple perspectives represented by the panelists. Provide the question which will be the subject of the debate.
  • ISPOR Guidance on the Use of AI-Assisted Technologies in Content: ISPOR has implemented guidance on the use of artificial intelligence (AI) and AI-assisted technologies in submission to the Society’s conferences. Submitting authors/submitters are required to disclose the use of AI and AI-assisted technologies in their submitted abstract(s) and/or accepted materials. Standard word processing spelling and grammar checks do not need to be disclosed. 
  • Joint Clinical Assessment/Scientific Advice in the EU Related Content: Given the ongoing development of the Joint Clinical Assessment process in the EU and the accompanying methods guidance, we anticipate that this will be a highly relevant topic at ISPOR. Similarly, Joint Scientific Consultations constitute an integral part of the EU HTA regulation and provide an opportunity to discuss the development plan to generate evidence to meet the needs of both regulators and HTA bodies with regards to pharmaceuticals and medical devices. Sessions specifically relevant to either the process or methods involved in these areas, especially the more controversial aspects, will be highlighted in our program.
  • RWE Related Content: All topics are welcome, but we also encourage the submission around the topic of real-world evidence.
  • Indicate if Submitter or Authors are Member(s) of an ISPOR Chapter
  • Level of Difficulty: Indicate if this session is Introductory, Intermediate, or Advanced in nature.

STEP 2: TAXONOMY/TOPIC

Select the taxonomy/topic that best describes your session.

Clinical Outcomes

Clinician Reported Outcomes

Comparative Effectiveness or Efficacy

Performance-based Outcomes

Clinician Outcomes Assessment

Relating Intermediate to Long-term Outcomes

Economic Evaluation

Cost/Cost of Illness/Resource Use Studies

Cost-comparison/effectiveness/utility/benefit Analysis

Budget Impact Analysis

Thresholds & Opportunity Cost

Trial-based economic evaluation

Work & Home Productivity - Indirect Costs

Value of Information

Novel & Social Elements of Value

Epidemiology & Public Health

Safety & Pharmacoepidemiology

Public Health

Prevalence, Incidence, & Disease Risk Factors

Disease Classification & Coding

 

Health Policy & Regulatory

Approval & Labeling

Pricing Policy & Schemes

Reimbursement & Access Policy

Insurance Systems & National Health Care

Public Spending & National Health Expenditures

Procurement Systems

Coverage with Evidence Development & Adaptive Pathways

Risk-sharing Approaches

Health Disparities & Equity

 

Health Service Delivery & Process of Care

Hospital and Clinical Practices

Prescribing Behavior

Pharmacist Interventions and Practices

Formulary Development

Telemedicine

Quality of Care Measurement

Disease Management

Treatment Patterns and Guidelines

Health Technology Assessment

Systems & Structure

Value Frameworks & Dossier Format

Decision & Deliberative Processes

 

Medical Technologies

Medical Devices

Digital Health

Diagnostics & Imaging

Implementation Science

 

Methodological & Statistical Research

Artificial Intelligence, Machine Learning, Predictive Analytics

Missing Data

Confounding, Selection Bias Correction, Causal Inference

Modeling & Simulation

PRO & Related Methods

Survey Methods

 

Patient-Centered Research

Adherence, Persistence, & Compliance

Stated Preference & Patient Satisfaction

Health State Utilities

Patient-reported Outcomes & Quality of Life Outcomes

Patient Behavior and Incentives

Patient Engagement

Instrument Development, Validation, & Translation

 

Organizational Practices

Academic & Educational

Industry

Ethical

Best Research Practices

Geographic & Regional

 

Real World Data & Information Systems

Data Protection, Integrity, & Quality Assurance

Health & Insurance Records Systems

Distributed Data & Research Networks

Reproducibility & Replicability

 

Study Approaches

Clinical Trials

Pragmatic Trials & Large Simple Trials

Prospective Observational Studies 

Electronic Medical & Health Records

Registries

Administrative Claims Data

Surveys & Expert Panels

Decision Modeling & Simulation

Literature Review & Synthesis

Meta-analysis & Indirect Comparisons

 

STEP 3: LOCATION

What geographical region is this content about?

STEP 4: MODERATOR/PANELISTS

An issue panel is comprised of 1 moderator and a minimum of 2 and maximum of 3 panelists. All moderator/panelists will be asked to provide any previous, relevant speaking/publication experience.

  • Moderators maintain communication with panelists and ISPOR staff regarding the development and delivery of the session.
  • To assure lively debate, panelists should be from different institutions and/or work environments representing different perspectives on the debate.
  • Panelists should present distinct views on the topic.
  • Provide the names, degrees, positions, city, state, country and email addresses for the moderator/panelists.
  • Panelist's Perspective: Provide a description of each panelist’s perspective on the debate topic.
    • Example 1: Dr. Doe will discuss challenges in designing a patient-centered value framework, including addressing tensions between the societal and patient perspective. Ms. Roe will represent patient perspectives, offering insights from patient-centered research conducted by CancerCare. She will highlight factors important to cancer patients and approaches to collecting such information in clinical practice to support a customized patient-centered decision tool.
    • Example 2: John Doe will argue that the development of open-source models is essential for cost-effectiveness analysis to be viewed as a reliable input to decision making and Jane Roe will argue that the impact on intellectual property rights, model “ownership”, oversite and, consequently, the incentives and resources available to develop and maintain models are prohibitive.
  • You will be asked for full submitter information on this step as well. The submitter can be the same as the moderator or panelist.

STEP 5: ISSUE/OVERVIEW

  • Length of Proposal (Issue and Overview): 300 words
    • ISSUE: Provide a clear definition of the issue to be presented and debated.
    • OVERVIEW: Provide background information and details on the material to be presented. Include speaker presentation length, e.g., 15 minutes, and state the allotted time to address the audience discussion and debate criterion. It is helpful to include which stakeholders will benefit from attending.

STEP 6: CONFIRMATION

Review your submission and complete the “Final Steps” acknowledgement form at the bottom. You must complete this final step and select “Conclude Submission,” otherwise your submission will be considered incomplete and not submitted for review. Please note: you will need to complete this step every time you update your submission.

 

 


CRITERIA FOR EVALUATION OF ISSUE PANELS

Overall, issue panel acceptance is based on the quality of the proposal/debate presented and the topic’s importance for inclusion and discussion in this conference’s scientific program.

Please consider the updated submission criteria when submitting your proposal:

Quality of content

  • Educational value of the session
  • Timeliness of the topic
  • Applicability of content to HEOR practice or principles
  • Effectiveness of incorporated active learning strategies
  • The information/issue presented are novel or innovative
  • Workshop proposals includes examples drawn from multiple sources
  • Unbiased content that does not promote a product, service, or organization; abstracts deemed to be promotional will be excluded from consideration

Quality of proposal

  • Plans for interactivity between the speakers and audience
  • Proposal purpose/issue is clearly defined
  • Issue panel proposals have more than one perspective identified
  • The background information (included in the overview) is clear and concise

Quality of Speakers

  • Expertise/experience of proposed speakers
  • Proposed speakers represent diverse backgrounds (gender, geographic, institutional - refer to ISPOR Diversity policy) and perspectives (multiple organizations are represented)
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×